- Home
- Companies
- Siolta Therapeutics
- Products
- Siolta - Model STMC-103H - Atopic ...
Siolta - Model STMC-103H -Atopic Dermatitis Treatment
The Power to Prevent: Allergic diseases, including atopic dermatitis, food allergy, allergic asthma, and allergic rhinitis, have a common underlying inflammatory cascade and often occur in a sequential order referred to as “the atopic march.” STMC-103H, also known as adored: allergic disease onset prevention study, is Siolta’s proof of concept study aimed at stopping allergic disease before it’s starts by targeting early intervention of infants at high risk for developing allergic diseases.
The current standard of care treatments such as antihistamines, steroids, bronchodilators, and biologics, target the downstream inflammation that results from an inappropriate immune response. In contrast, Siolta Therapeutic’s microbiome-based approach towards atopic diseases aims to prevent the initiation of the immune dysfunction cascade, thus preventing allergic disease before it starts. Our preclinical proof of concept studies provide evidence that oral supplementation with STMC-103H has the potential to alter the gut microbiome, reprogram metabolism, reduce immune activation, and thus protect against allergic inflammation.
